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ABSTRACT
Background: Although increased fruit intake reduces cardiovascular
disease (CVD) risk, which fruits are most beneficial and what key
constituents are responsible are unclear. Habitual intakes of flavo-
noids, specifically anthocyanins and flavanones, in which .90% of
habitual intake is derived from fruit, are associated with decreased
CVD risk in women, but associations in men are largely unknown.
Objective:We examined the relation between habitual anthocyanin
and flavanone intake and coronary artery disease and stroke in the
Health Professionals Follow-Up Study.
Design: We followed 43,880 healthy men who had no prior diag-
nosed CVD or cancer. Flavonoid intake was calculated with the use
of validated food-frequency questionnaires.
Results: During 24 y of follow-up, 4046 myocardial infarction (MI)
and 1572 stroke cases were confirmed by medical records. Although
higher anthocyanin intake was not associated with total or fatal MI
risk, after multivariate adjustment an inverse association with non-
fatal MI was observed (HR: 0.87; 95% CI: 0.75, 1.00; P = 0.04;
P-trend = 0.098); this association was stronger in normotensive
participants (HR: 0.81; 95% CI: 0.69, 0.96; P-interaction =
0.03). Anthocyanin intake was not associated with stroke risk.
Although flavanone intake was not associated with MI or total
stroke risk, higher intake was associated with a lower risk of
ischemic stroke (HR: 0.78; 95% CI: 0.62, 0.97; P = 0.03, P-trend =
0.059), with the greatest magnitude in participants aged $65 y
(P-interaction = 0.04).
Conclusions: Higher intakes of fruit-based flavonoids were associated
with a lower risk of nonfatal MI and ischemic stroke in men. Mecha-
nistic studies and clinical trials are needed to unravel the differential
benefits of anthocyanin- and flavanone-rich foods on cardiovascular
health. Am J Clin Nutr doi: 10.3945/ajcn.116.133132.
Keywords: flavonoids, anthocyanins, flavanones, heart disease,
stroke, men
INTRODUCTION
Recent data suggest that dietary fruit intake is the third most
important modifiable risk factor for reducing global rates of
noncommunicable diseases after high blood pressure and
smoking (1). However, individual fruits might not be equally
associated with health, and which fruits are most beneficial and
what key constituents are responsible for the health benefits
remain to be established. Recent prospective data provide evi-
dence that suggests beneficial effects of higher intakes of specific
fruits, including blueberries and grapes, for reducing the risk of
type 2 diabetes (2), and growing evidence highlights the bene-
ficial effect of specific flavonoids from plant bioactive com-
pounds present in fruits that improve endothelial function, blood
pressure, and insulin sensitivity (3–7). Thus, flavonoids might be
key constituents of fruits that decrease the risk of cardiovascular
disease (CVD),7 a major contributor to morbidity and mortality
(8–10).
Although fruit contributes to the intake of several different
flavonoid subclasses, in the habitual diet .90% of the intake of
2 main subclasses of flavonoids, anthocyanins and flavanones, is
derived from fruit (3, 6). Supportive data for their effects on
vascular function come from mechanistic studies and show that
their downstream metabolites can alter signaling pathways in-
volved in vascular inflammation, inhibit atherosclerosis devel-
opment, improve endothelial function principally via improved
blood flow, enhance production or reduce NAD(P)H oxidase-
dependent elimination of endothelial nitric oxide, and inhibit
platelet function (11–14). Relative to other flavonoid subclasses,
there have been limited trials to our knowledge that have ex-
amined the impact of anthocyanins and flavanones on CVD risk
factors. In several short-term interventions, anthocyanin- or
flavanone-rich foods resulted in reductions in both systolic and
diastolic blood pressure and favorable changes in arterial stiff-
ness, although whether the benefits are greater in nonmedicated
participants has to our knowledge not yet been examined (13,
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15–20). Anthocyanins have been shown to exert beneficial ef-
fects on total and LDL cholesterol concentrations, with some
evidence that the effect is mediated by improvements in cho-
lesterol efflux capacity (21, 22). Recent trial evidence supports
an anti-inflammatory effect of anthocyanins in patients with
hypercholesterolemia (23), and recent cross-sectional data pro-
vide supporting evidence that suggests that an anti-inflammatory
effect may be a key component underlying the reduction in risk
associated with higher habitual anthocyanin intake (7).
With a few exceptions, most of the prospective studies that
have examined associations between total and flavonoid sub-
classes on CVD risk have focused on women (6, 24–29). Several
studies were unable to determine flavanones and anthocyanin
intake accurately because they were poorly captured in earlier
food compositional databases (29–31). Our focus on anthocya-
nins and flavanones stems from our previous studies in women,
in which we observed an inverse association between the intake
of flavanones and risk of ischemic stroke and among younger
women higher habitual anthocyanin intake and a lower risk of
nonfatal myocardial infarction (MI) (6, 26). Based on these data,
we hypothesized a priori that a higher intake of anthocyanins
would be associated with a reduced risk of MI in men and
a higher habitual intake of flavanones would be associated with
a reduced risk of ischemic stroke.
METHODS
Study population
In 1986, 51,529 men aged 32–81 y were enrolled in the Health
Professionals Follow-Up Study. Each participant returned
a questionnaire by mail on lifestyle and medical history and re-
ceived follow-up questionnaires biennially to record newly di-
agnosed illnesses and to update lifestyle factors. Beginning in
1986, every 4 y participants completed semiquantitative food-
frequency questionnaires (FFQs) (32, 33). Participants who re-
ported a history of MI, stroke, angina, other CVDs or coronary
bypass surgery, or cancer (except nonmelanoma skin cancer) at
baseline were excluded. Participants who were missing dietary
data at baseline or had implausible values for total caloric intake
(,800 or .4200 kcal/d) were also excluded, resulting in the
inclusion of 43,880 men in these analyses. The institutional
review board at the Harvard T.H. Chan School of Public Health
reviewed and approved this study, and participants provided
implied consent by virtue of returning their questionnaires.
Outcome assessment
The outcomes were incident MI [which included nonfatal MI and
fatal coronary artery disease (CAD)] and stroke (ischemic and
hemorrhagic) that occurred after the return of the 1986 questionnaire
and before January 2010. We requested permission to review the
medical records of all participants who reported a physician di-
agnosis of a CAD or stroke during follow-up. Physicians blinded to
risk factor status reviewed all relevant records to confirm all cases.
Nonfatal MI was confirmed if data in the medical records met
WHO criteria based on symptoms plus either diagnostic electro-
cardiographic changes or elevated cardiac enzyme concentrations
(34). Fatal CADwas defined as a fatal MI if confirmed by hospital
records, autopsy, or if CAD was listed on the death certificate as
the cause of death and evidence of previous CAD was available.
Stroke, cerebrovascular pathology caused by infection, trauma, or
malignancy was excluded, and “silent” strokes discovered only by
radiologic imaging were also excluded. Strokes were confirmed with
the use of the National Survey of Stroke criteria (35), which requires
a neurological deficit of rapid or sudden onset lasting$24 h or until
death. Fatal strokes were identified by next of kin, postal authorities,
or the National Death Index and confirmed by medical records,
autopsy reports, and death certificates with stroke listed as the un-
derlying cause. We categorized types of stroke as ischemic (embolic
or thrombotic), hemorrhagic (subarachnoid or intraparenchymal),
and unknown. Strokes that required hospitalization and for which
confirmatory information was obtained but medical records were
unavailable were designated as probable (25% of total strokes).
Because the exclusion of probable strokes did not alter the results,
we included both confirmed and probable strokes in this analysis.
Dietary assessment
Dietary intake data were collected from participants in 1986 and
subsequently every 4 y. A database for assessment of intake of the
different flavonoid subclasses was constructed as previously de-
scribed (5). Briefly, intakes of individual compounds (energy-
adjusted aglycone equivalents) were calculated as the sum of the
consumption frequency of each food multiplied by the content of
the specific flavonoid (aglycone equivalents) for the specified por-
tion size. We derived intakes of flavanones (eriodictyol, hesperetin,
naringenin) and anthocyanins (cyanidin, delphinidin, malvidin,
pelargonidin, petunidin, peonidin). The validity and reproducibility
of the FFQs have been reported previously. Correlations between
major dietary sources of flavonoids, including anthocyanins and
flavanones (fruits, vegetables, tea, wine) measured by diet records
and FFQs, were 0.70, 0.50, 0.77, and 0.83, respectively (36, 37);
similar correlations were observed between several urinary flavo-
noid biomarkers and fruit and vegetable intake (0.43–0.66) (38).
Statistical methods
Participants contributed person-time from the date of return of the
1986 questionnaire to the date of MI or stroke diagnosis, death, or
the end of follow-up (January 2010). We used left-truncated Cox
proportional hazards regression models with time-varying cova-
riates, with a counting process data structure and age in years as the
time scale, stratifying additionally on calendar year (39) to estimate
the HR for MI risk and stroke with the use of the lowest flavonoid
intake quintile as the referent group. We controlled for BMI
(in kg/m2) (,25, 25–29.9, or $30), physical activity (metabolic
equivalents/wk in quintiles), alcohol consumption (0, 0.1–4.9,
5–14.9, 15–29.9, or $30 g/d), smoking (never, past, or current:
1–14 or $15 cigarettes/d), marital status, history of hypertension,
history of hypercholesterolemia, quintiles of energy intake, cereal
fiber, fat intake (SFAs, PUFAs, or trans fatty acids) and folate,
and family history of MI. We defined subgroup analyses a priori to
examine effect modification by age (participants aged ,65 or
$65 y), the presence of type 2 diabetes mellitus, and hypertension.
All analyses were conducted with SAS software version 9.2 (SAS
Institute). All P values were 2-sided.
RESULTS
During 24 y of follow-up among the 43,880 men, 4046 cases of
MI (2222 nonfatal) and 1572 cases of stroke (901 ischemic stroke
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cases) were reported. Baseline characteristics of the participants
according to quintiles of anthocyanin intake are shown in Table 1.
The median age of cases at baseline was 53 y, with an age range
of 39–77 y. Men with higher anthocyanin intake smoked less, ex-
ercised more, and had a lower intake of saturated fat, energy, and
alcohol and higher cereal fiber intakes. Anthocyanin intake ranged
from 0 to 613 mg/d (IQR: 3.9–15.7 mg/d) and flavanone intake
from 0 to 728 mg/d (IQR: 18.8–70.9 mg/d). Participant charac-
teristic trends were similar across quintiles of flavanones (Sup-
plemental Table 1).
Although anthocyanin intake was inversely associated with MI
risk (total, fatal, and nonfatal) in age-adjusted models, after
TABLE 1
Baseline characteristics of men from the Health Professionals Follow-Up Study by quintile of anthocyanin intake (1986)1
Anthocyanin intake, mg/d
Quintile 1
(n = 8779)
Quintile 2
(n = 8764)
Quintile 3
(n = 8786)
Quintile 4
(n = 8776)
Quintile 5
(n = 8775) P-trend
Age, y 53.3 6 9.7 53.0 6 9.5 52.9 6 9.5 53.2 6 9.5 53.6 6 9.5 —
BMI, kg/m2 25.6 6 3.4 25.6 6 3.4 25.5 6 3.4 25.4 6 3.3 25.3 6 3.2 ,0.0001
Smoking, %
Never 45 50 52 53 54 ,0.0001
Former 41 40 40 40 41 0.38
Current 14 9 8 7 6 ,0.0001
Physical activity, METs/wk 17.7 6 27.7 19.7 6 26.6 21.4 6 30.6 22.4 6 27.5 24.8 6 34.1 ,0.0001
Family history of MI, % 12 12 11 12 13 0.52
History of hypertension, % 22 20 19 20 19 0.0002
History of diabetes, % 3 2 3 2 3 0.03
History of hypercholesterolemia, % 10 10 11 11 12 ,0.0001
Energy intake, kcal/d 2050 6 656 2020 6 595 2051 6 697 2100 6 568 1748 6 506 ,0.0001
Alcohol, g/d 13.3 6 18.7 10.6 6 14.6 11.1 6 14.7 11.5 6 14.4 10.5 6 14.2 ,0.0001
SFAs, g/d 26.7 6 6.6 25.6 6 5.9 24.6 6 5.8 23.9 6 5.7 22.5 6 6.0 ,0.0001
MUFAs, g/d 28.9 6 6.2 28.3 6 5.8 27.6 6 5.8 26.8 6 5.7 25.4 6 6.0 ,0.0001
PUFAs, g/d 13.2 6 3.8 13.4 6 3.4 13.3 6 3.4 13.2 6 3.4 12.9 6 3.4 ,0.0001
trans Fatty acids, g/d 3.1 6 1.2 3.0 6 1.1 2.8 6 1.1 2.7 6 1.1 2.5 6 1.1 ,0.0001
Cereal fiber, g/d 5.3 6 4.0 5.7 6 3.6 5.9 6 4.3 6.0 6 3.7 6.3 6 4.0 ,0.0001
AHEI score 42.2 6 10.7 45.8 6 10.5 48.2 6 10.5 49.9 6 10.6 51.7 6 10.6 ,0.0001
Flavanones, mg/d 42.2 6 44.5 48.3 6 42.7 51.6 6 44.3 54.7 6 43.3 62.2 6 48.7 ,0.0001
1Values are age-adjusted (except for age) means 6 SDs, unless otherwise specified. Intakes of SFAs, MUFAs, PUFAs, trans fatty acids, and cereal fiber
are energy-adjusted values. AHEI, Alternative Healthy Eating Index; MET, metabolic equivalent task; MI, myocardial infarction.
TABLE 2
Relation between flavanone and anthocyanin intake and MI in participants from the Health Professionals Follow-Up Study1
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P-trend
Flavanones, mg/d 7.5 23.6 43.5 64.5 103.9
Total MI cases, n/person-years 844/174,303 761/176,057 792/173,908 819/168,361 830/164,287
Age-adjusted 1.0 0.89 (0.80, 0.98) 0.86 (0.78, 0.94) 0.86 (0.78, 0.95) 0.86 (0.78, 0.94) 0.006
Multivariable 1.0 0.96 (0.87, 1.06) 0.96 (0.87, 1.06) 0.99 (0.89, 1.09) 0.98 (0.88, 1.08) 0.87
Nonfatal MI cases, n 490 405 439 444 444
Age-adjusted 1.0 0.82 (0.72, 0.94) 0.85 (0.75, 0.97) 0.87 (0.76, 0.99) 0.86 (0.76, 0.98) 0.15
Multivariable 1.0 0.87 (0.76, 0.99) 0.93 (0.82, 1.06) 0.98 (0.85, 1.12) 1.01 (0.88, 1.16) 0.34
Fatal MI cases, n/person-years 350/174,303 354/176,057 352/173,908 375/168,361 385/164,287
Age-adjusted 1.0 0.98 (0.85, 1.14) 0.87 (0.75, 1.01) 0.86 (0.75, 1.00) 0.86 (0.74, 0.99) 0.02
Multivariable 1.0 1.10 (0.95, 1.28) 1.01 (0.87, 1.18) 1.01 (0.87, 1.18) 0.95 (0.81, 1.11) 0.22
Anthocyanins, mg/d 1.9 4.5 7.8 13.7 26.3
Total MI cases, n/person-years 863/167,657 833/171,701 793/173,427 814/173,317 743/170,814
Age-adjusted 1.0 0.96 (0.87, 1.05) 0.89 (0.81, 0.98) 0.90 (0.82, 0.99) 0.82 (0.74, 0.90) ,0.0001
Multivariable 1.0 1.04 (0.94, 1.14) 1.00 (0.90, 1.10) 1.04 (0.94, 1.14) 0.97 (0.87, 1.07) 0.44
Nonfatal MI cases, n 482 448 443 469 380
Age-adjusted 1.0 0.92 (0.81, 1.04) 0.90 (0.79, 1.02) 0.94 (0.83, 1.07) 0.76 (0.66, 0.87) 0.0002
Multivariable 1.0 0.96 (0.84, 1.09) 0.97 (0.85, 1.10) 1.04 (0.91, 1.18) 0.87 (0.75, 1.00) 0.098
Fatal MI cases, n/person-years 379/167,657 384/171,701 349/173,427 343/173,317 361/170,814
Age-adjusted 1.0 1.01 (0.88, 1.17) 0.89 (0.77, 1.03) 0.85 (0.73, 0.98) 0.88 (0.77, 1.02) 0.04
Multivariable 1.0 1.14 (0.99, 1.32) 1.02 (0.88, 1.19) 1.03 (0.88, 1.20) 1.10 (0.94, 1.28) 0.56
1Values are HRs (95% CIs) unless otherwise specified; median intakes are expressed as mg/d. The multivariable model was adjusted for age, physical
activity, smoking, BMI, alcohol, energy, cereal fiber, folate, SFAs, PUFAs, trans fatty acids, marital status, hypertension, hypercholesterolemia, and family
history of MI. MI, myocardial infarction.
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additionally adjusting for lifestyle, diet, and health status the re-
duction in risk was only statistically significant for nonfatal MI risk
(Table 2). After multivariate adjustment, a higher habitual intake of
anthocyanins was associated with a 14% lower risk of nonfatal MI
(HR: 0.87; 95% CI: 0.75, 1.00; P-trend = 0.098) (Table 2). We also
examined the association between extreme deciles of anthocyanin
intake and nonfatal MI risk [median intake: 0.97 mg/d in the bot-
tom decile and 35.9 mg/d in the top decile; RR: 0.81 (95% CI: 0.67,
0.99)] in fully adjusted models. In stratified analyses, we found
that the inverse association was stronger in participants who were
not hypertensive (HR: 0.81; 95% CI: 0.69, 0.96) than participants
diagnosed with hypertension (HR: 1.05; 95% CI: 0.79, 1.39;
P-interaction = 0.03). In participants with diabetes (HR: 0.97; 95%
CI: 0.65, 1.45), the inverse association between anthocyanin intake
and nonfatal MI was not significantly different from men who did
not have diabetes (HR: 0.85; 95% CI: 0.73, 0.99; P-interaction =
0.67). When we restricted our analyses to men #65 y in other
stratified analyses, the results did not change (data not shown).
Although anthocyanin intake was not associated with a lower risk
of stroke, higher flavanone intakewas associated with a lower risk of
ischemic stroke (HR: 0.78; 95% CI: 0.62, 0.97; P-trend = 0.059).
This inverse association was present only in men aged.65 y (HR:
0.71; 95% CI: 0.54, 0.92) compared with men #65 y (HR: 1.0;
95% CI: 0.66, 1.51; P-interaction = 0.04). In other stratified anal-
yses, we found that the inverse association was similar in those with
and without hypertension (data not shown). Flavanone intake was
not associated with nonfatal MI risk after multivariate adjustment,
and we observed no associations between anthocyanin intake and
fatal MI risk or hemorrhagic stroke (Tables 2 and 3). For flava-
nones, we observed no associations with fatal MI risk, although we
observed a positive association between intake and the risk of
hemorrhagic stroke (n = 225 cases). When we restricted follow-up
to 1998 (12 y), the findings did not change (data not shown).
DISCUSSION
In this prospective cohort study of well-characterized men
with 24 y of follow-up, we observed that a higher intake of
anthocyanins was associated with a 14% lower risk of nonfatal
MI and a higher intake of flavanones was associated with a 22%
lower risk of ischemic stroke; these inverse associations were
independent of established dietary and nondietary CVD risk
factors. These compounds are commonly consumed through
fruit intake because they are present in either red or blue fruits
(anthocyanins) or citrus fruits (flavanones) and therefore
readily incorporated into the habitual diet (Table 4) (40, 41). A
simple dietary change therefore has the potential to have
a considerable population-level impact on CVD prevention
efforts in men.
To date, the few prospective cohort studies that have examined
associations between habitual anthocyanin intake and CVD risk
have predominantly focused on women. Evidence has suggested
that increased intake is associated with a lower risk of nonfatal
MI, with the greatest magnitude of association observed in
younger women (6, 24). In the 2 studies that have previously
examined the relation between anthocyanin intake and CVD
mortality, beneficial effects were only observed in women, and an
earlier study based on early flavonoid composition databases
found no association (25, 30). For stroke, in agreement with our
previous findings, there is currently no evidence to our knowledge
for a beneficial effect of higher anthocyanin intake in either men
or women (24–26, 30). However, a higher habitual flavanone
intake was associated with a 19% lower risk of ischemic stroke
in 69,622 women over 14 y of follow-up (26), which is similar in
magnitude to the risk reduction we observed in men (22%). Our
study therefore provides novel data that support a beneficial
association between a higher habitual intake of flavanones
and lower risk of ischemic stroke and higher anthocyanin intake
TABLE 3
Relation between flavanone and anthocyanin intake and risk of stroke in participants from the Health Professionals Follow-Up Study1
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P-trend
Flavanones, mg/d 7.5 23.6 43.5 64.5 103.9
Total stroke cases, n/person-years 316/179,004 296/179,926 313/177,867 316/172,733 331/168,344
Age-adjusted 1.0 0.93 (0.79, 1.09) 0.89 (0.76, 1.05) 0.87 (0.75, 1.02) 0.89 (0.76, 1.04) 0.14
Multivariable 1.0 0.96 (0.82, 1.13) 0.94 (0.80, 1.10) 0.92 (0.78, 1.08) 0.95 (0.80, 1.12) 0.51
Ischemic stroke cases, n/person-years 200/179,004 173/179,926 168/177,867 188/172,733 172/168,344
Age-adjusted 1.0 0.86 (0.70, 1.05) 0.76 (0.62, 0.94) 0.83 (0.68, 1.02) 0.74 (0.60, 0.91) 0.01
Multivariable 1.0 0.88 (0.71, 1.08) 0.79 (0.64, 0.98) 0.87 (0.70, 1.07) 0.78 (0.62, 0.97) 0.059
Hemorrhagic stroke cases, n/person-years 31/179,004 46/179,926 49/177,867 47/172,733 54/168,344
Age-adjusted 1.0 1.48 (0.94, 2.34) 1.44 (0.92, 2.27) 1.34 (0.85, 2.12) 1.50 (0.96, 2.34) 0.22
Multivariable 1.0 1.58 (1.00, 2.51) 1.53 (0.96, 2.43) 1.41 (0.88, 2.27) 1.75 (1.09, 2.82) 0.09
Anthocyanins, mg/d 1.9 4.5 7.8 13.7 26.3
Total stroke cases, n/person-years 346/172,074 314/176,190 281/177,780 303/177,669 328/174,162
Age-adjusted 1.0 0.90 (0.77, 1.05) 0.79 (0.67, 0.93) 0.84 (0.72, 0.98) 0.89 (0.77, 1.04) 0.42
Multivariable 1.0 0.96 (0.82, 1.12) 0.86 (0.73, 1.00) 0.90 (0.77, 1.06) 1.00 (0.85, 1.17) 0.71
Ischemic stroke cases, n/person-years 200/172,074 178/176,190 176/177,780 168/177,669 179/174,162
Age-adjusted 1.0 0.88 (0.72, 1.08) 0.86 (0.70, 1.05) 0.81 (0.66, 0.99) 0.85 (0.69, 1.04) 0.17
Multivariable 1.0 0.94 (0.76, 1.15) 0.93 (0.75, 1.14) 0.86 (0.70, 1.06) 0.93 (0.75, 1.15) 0.51
Hemorrhagic stroke cases, n/person-years 48/172,074 58/176,190 32/177,780 42/177669 47/174162
Age-adjusted 1.0 1.21 (0.83, 1.78) 0.64 (0.41, 1.00) 0.84 (0.55, 1.26) 0.92 (0.62, 1.38) 0.50
Multivariable 1.0 1.26 (0.86, 1.86) 0.70 (0.44, 1.10) 0.88 (0.58, 1.35) 1.06 (0.69, 1.61) 0.93
1Values are HRs (95% CIs) unless otherwise specified; median intakes are expressed as mg/d. The multivariable model was adjusted for age, physical
activity, smoking, BMI, alcohol, energy, cereal fiber, folate, SFAs, PUFAs, trans fatty acids, marital status, hypertension, hypercholesterolemia, and family
history of myocardial infarction.
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and lower risk of nonfatal MI in men. The reasons for these
differential associations with CVD risk are unclear, but of all of
the flavonoid subclasses, flavanones are one of the best absorbed
and most effective at crossing the blood-brain barrier (42, 43),
inhibiting platelet function, and decreasing plaque progression
(3, 14). In addition, one flavanone, naringenin, has been shown
to localize in the brain after oral ingestion (44). This may pro-
vide support for the inverse association between flavanones and
risk of ischemic stroke, whereas anthocyanins may be inversely
associated with nonfatal MI risk through mechanisms related to
improvements in cholesterol efflux capacity or a reduced sus-
ceptibility of the myocardium to ischemia or reperfusion injury
(12, 22). Of interest, in previous food-based analyses we found
that a higher fruit and vegetable intake was associated with
a 19% reduction in nonfatal MI risk but only marginally asso-
ciated with fatal CHD, which is similar to our lack of association
for anthocyanin intake and fatal MI risk (45). Together, these
population-based data support the available mechanistic find-
ings that flavonoids primarily exert their cardioprotective effects
by reducing blood pressure, endothelial function, and insulin
sensitivity (3–7).
It is also interesting to note that the magnitude of the inverse
association between flavanone intake and risk of ischemic stroke
was most pronounced in the participants aged$65 y, whereas the
association between anthocyanin intake and risk of nonfatal MI
did not differ in younger or older men. However, we did see that
the inverse association was stronger in participants who were not
hypertensive than in those taking hypertensive medication.
Therefore, in this cohort of older men aged 40–75 y at baseline
who were followed for .24 y, medication use may have ex-
ceeded the capacity for dietary constituents such as fruit-based
flavonoids to reduce the risk of CVD in older individuals. These
data reinforce the importance of dietary intervention strategies
for CVD prevention.
Although the overall range in anthocyanin and flavanone intake
was similar across the cohort (0–613 mg/d for anthocyanin intake
and 0–728 mg/d for flavanones), the variability in intake across the
middle 3 quintiles was only 9 mg for anthocyanins and 41 mg for
flavanones. With such small differences in the distribution of an-
thocyanin intake, measurement error or misclassification is likely
to be greatest. When we compared extreme deciles of intake,
those in the top decile of anthocyanin intake (median intake:
35.9 mg/d) had a 19% lower risk of nonfatal MI, suggesting
potentially greater benefits at higher intakes. However, for fla-
vanones, with a wide range in intake across quintiles (median
intake: 7.5 mg/d in quintile 1 and 103.9 mg/d in quintile 5), we
observed a threshold effect and did not see any further reduction
in risk when we compared extreme deciles of intake. To our
knowledge, very few dose-response trials on anthocyanins and
flavanones and biomarkers of CVD risk have been conducted,
but given our knowledge of other subclasses, including the
isoflavones and flavan-3-ols, there is likely a threshold of intake
required for a biological effect, and very low concentrations of
intake are unlikely to be bioactive (46, 47).
Intriguingly, to our knowledge only a few randomized con-
trolled trials have examined the impact of anthocyanins and
flavanones on cardiometabolic health relative to other flavonoids
such as the flavan-3-ols present in tea and cocoa and the iso-
flavones present in soy (48). In several short-term interventions
(,2 mo), anthocyanin-rich food intake (predominantly consumed
as blueberries) resulted in a reduction in both systolic and di-
astolic blood pressure (15–17) and favorable changes in arterial
stiffness (17, 18). A recent 3-mo dose-response study in which
participants consumed a strawberry beverage equivalent to 250
and 500 g fresh strawberries/d (containing 78 and 155 mg an-
thocyanins/d) demonstrated beneficial effects on total and
LDL cholesterol concentrations in the high intake group (21),
potentially mediated by improvements in cholesterol efflux
capacity (22). In a 6-mo study, a considerable decrease in in-
flammatory biomarkers after the intake of purified anthocyanins
(320 mg/d) in patients with hypercholesterolemia (23) was ob-
served, whereas a single dose of a strawberry beverage (con-
taining 39 mg anthocyanins) attenuated the 6-h postprandial
inflammatory response to a high-carbohydrate and moderate-fat
meal in overweight dyslipidemic participants (49). These data
are supported by a growing body of evidence from animal
models and in vitro experiments that have shown a cardio- and
neuroprotective role. Anthocyanins and their metabolites tra-
verse the blood-brain barrier (50) and in animal models inhibit
atherosclerosis development, alter cell signaling pathways in-
volved in vascular inflammation, attenuate cyclophospamide-
induced cardiac injury, and reduce infarct size after coronary
occlusion and perfusion (11, 12, 51).
For flavanones, animal and in vitro data also support cardio-
and neuroprotective effects (3, 13, 42, 43, 52, 53). Flavanones and
their metabolites improve endothelial function principally via
improved blood flow, enhanced production or reduced NAD(P)H
oxidase-dependent elimination of endothelial nitric oxide, and
inhibited platelet function (14). These mechanisms may under-
line the observed beneficial effect on ischemic stroke but no
observed effect in relation to hemorrhagic stroke, which is more
likely related to mechanisms that interfere with platelet function
TABLE 4
Common sources of anthocyanins and flavanones1
mg/100 g2 Serving size mg/serving
Anthocyanins
Blueberries 163.3 1/2 cup 120.8
Blackberries 100.6 1/2 cup 70.4
Black plums 56.0 1 medium 37.0
Red grapes 48.0 1/2 cup 36.5
Raspberries 48.6 1/2 cup 30.2
Red wine 19.3 5 oz 28.3
Cherries 32.0 1/2 cup 22.4
Strawberries 27.0 1/2 cup 20.5
Flavanones
Orange (fresh/raw) 42.6 1 medium 55.8
Orange juice (fresh/raw) 14.3 6 oz 27.2
Orange juice (chilled) 19.0 6 oz 35.3
Orange juice (blood) 14.4 6 oz 26.8
Grapefruit (fresh/raw) 54.5 0.5 medium 69.8
Grapefruit (fresh/raw—pink) 33.0 0.5 medium 42.2
Grapefruit juice (white) 21.2 6 oz 39.2
Grapefruit juice (pink) 17.8 6 oz 32.9
Lemon (fresh/raw) 49.8 1 medium (58 g) 28.9
Lemon juice 20.7 38 g 7.9
Lime (fresh/raw) 47.4 1 medium (55 g) 26.1
Lime juice 11.5 38 g 4.4
Tangerine (fresh/raw) 18.0 1 medium (84 g) 15.1
11 cup = 225 g; 1 oz = 28 g.
2Based on reference 41.
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and clotting. Our results for hemorrhagic stroke may also relate to
the small number of cases (n = 227). In vitro, the flavanone
aglycones naringenin and hesperetin exert a diverse array of
potentially anti-inflammatory effects by interacting with mitogen-
activated protein kinase, P13 kinase/Akt, and protein kinase C
signaling pathways (52, 54). In mice fed a high-fat diet sup-
plemented with a nutritionally relevant dose of naringin (the
glycoside of naringenin), a 41% decrease in plaque progression
was observed (3), suggesting that antiatherogenic effects of fla-
vanones are achievable at dietary-relevant doses. To our knowl-
edge, only a handful of placebo-controlled trials with flavanones
have been conducted to date. The first long-term trial, a 6-mo
flavanone intervention trial with grapefruit juice (containing
210 mg naringenin glycosides/d) in healthy postmenopausal women
improved arterial stiffness (19). In another 2-mo intervention with
flavanone-rich orange juice, global cognitive function was im-
proved (55), which is consistent with effects previously observed
in animal models (44). In 2 short-term trials (3–4 wk), impro-
vements in endothelial function, endothelium-dependent micro-
vascular reactivity, and a reduction in diastolic blood pressure
were observed (13, 20), and plasma hesperetin metabolites (phase
II) were associated with the beneficial effects on endothelial
function (20).
In the habitual diet, flavanones are almost exclusively asso-
ciated with citrus fruits, with higher concentrations present in
whole fruits than in products such as juices (Table 4) (40, 41)
because the solid parts of the fruit, particularly the albedo (white
spongy section) and the membranes separating the segments,
contain higher concentrations than the juice vesicles (pulp) (56).
Although on average, blueberries contain the highest concen-
trations of anthocyanins, a range of other fruits also have the
potential to contribute to anthocyanin intake, including other
berries, grapes, and grape-derived products including wine
(Table 4) (40, 41). Together, these data show that these fruit-
based flavonoids can be readily incorporated into the diet.
The strengths of this study include its prospective design, large
sample size with long-term follow-up, detailed data on important
risk factors and confounders, and comprehensive assessment of
habitual anthocyanin and flavanone intake. The limitations of our
study also warrant discussion. Although we adjusted for possible
confounders that are strongly associated with MI and stroke risk
(including BMI, smoking, and family history), there is still the
possibility of residual or unmeasured confounding from addi-
tional unmeasured factors or measurement error, which may be
greatest when comparing those consuming the highest and lowest
concentrations of anthocyanins. However, given our detailed
adjustment for a comprehensive set of confounders, it is unlikely
that these unmeasured factors would account fully for the ob-
served results.
The flavonoid content of foods varies depending on growing
conditions and manufacturing processes, but despite this varia-
tion, these data allow us to rank intakes and compare high and low
intakes in large population groups. There are currently no specific
biomarkers for anthocyanins to our knowledge because they are
extensively degraded after intake, including the production of an
extensive range of microbially derived metabolites, supporting
a strong interplay between anthocyanins and the microbiome
(57–59). For flavanones, recent methodologic developments
provide potential biomarkers for an objective assessment of this
subclass in future studies (60). The future direction is to identify
and develop validated and robust biomarkers that will best reflect
intake and differential metabolism of anthocyanins and flava-
nones. This will allow us to more accurately determine optimal
intakes of these compounds to reduce CVD risk. It is possible that
our findings might have been caused by other constituents found
in the foods that contribute most to this subclass; however,
the addition of other potentially beneficial constituents of fruits,
including fiber and folate, to our multivariate model did not
substantially attenuate the observed relations, suggesting that
anthocyanins and flavanones may be another important car-
dioprotective constituent. However, in a population-based study
such as ours it is impossible to disentangle the relative influence
of all constituents of fruits.
Our findings suggest that bioactive compounds present in both
citrus and red- or blue-colored fruits commonly consumed in the
habitual diet may be associated with a lower risk of CVD in men.
Further prospective studies are needed to confirm these associ-
ations, including studies with biomarkers of CVD risk to elu-
cidate mechanisms. Randomized trials focusing on commonly
consumed anthocyanin- and flavanone-rich foods are also needed
to examine dose-response effects, as are trials of longer duration
to assess clinically relevant endpoints.
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